Complications of Transplant for Nonmalignant Disorders: Autoimmune Cytopenias, Opportunistic Infections, and PTLD

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Dvorak, Christopher C ^a   Bollard, Catherine M ^b   El Bietar, Javier ^b   Filipovich, Alexandra ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA2B INTERFERON; CORTICOSTEROID; CYCLOSPORIN; FLUCONAZOLE; IMMUNOGLOBULIN; METHOTREXATE; RAPAMYCIN; RITUXIMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; BONE MARROW TRANSPLANTATION; CANDIDEMIA; CELL THERAPY; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DONOR LYMPHOCYTE INFUSION; EPSTEIN BARR VIRUS; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; INVASIVE ASPERGILLOSIS; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; RETICULOCYTE COUNT; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; VIRUS LATENCY; VIRUS REACTIVATION; WISKOTT ALDRICH SYNDROME;

BONE MARROW TRANSPLANTATION; DIABETES MELLITUS, TYPE 1; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; OPPORTUNISTIC INFECTIONS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855380462     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.024     Document Type: Article

References (97)

1. MacMillan M., Davies S., Nelson G., et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008, 14:16-22.
2. Arkwright P.D., Abinun M., Cant A.J. Autoimmunity in human primary immunodeficiency diseases. Blood 2002, 99:2694-2702.
3. Elhasid R., Bergman R., Etzioni A. Autoimmunity in severe combined immunodeficiency (SCID). Blood 2002, 100:2677-2678. author reply 8-9.
4. Etzioni A. Immune deficiency and autoimmunity. Science 2003, 364-369.
5. Goyal R., Bulua A.C., Nikolov N.P., Schwartzberg P.L., Siegel R.M. Rheumatologic and autoimmune manifestations of primary immunodeficiency disorders. Curr Opin Rheumatol 2009, 21:78-84.
6. Sherer Y., Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant 1998, 22:873-881.
7. Dupuis-Girod S., Medioni J., Haddad E., et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003, 111(Pt 1):e622-e627.
8. Chen X., Vodanovic-Jankovic S., Johnson B., Keller M., Komorowski R., Drobyski W.R. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007, 110:3804-3813.
9. Tivol E., Komorowski R., Drobyski W.R. Emergent autoimmunity in graft-versus-host disease. Blood 2005, 105:4885-4891.
10. Horn B., Viele M., Mentzer W., Mogck N., DeSantes K., Cowan M. Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation. Bone Marrow Transplant 1999, 24:1009-1013.
11. Moratto D., Giliani S., Bonfim C., et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011, 118:1675-1684.
12. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008, 111:439-445.
13. Bonduel M., Zelazko M., Figueroa C., Magaldi G., Rossi J., del Pozo A. Successful treatment of autoimmune hemolytic anemia with rituximab in a child with severe combined immunodeficiency following nonidentical T-cell-depleted bone marrow transplantation. Bone Marrow Transplant 2005, 35:819-821.
14. Raj K., Narayanan S., Augustson B., et al. Rituximab is effective inthe management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplant 2005, 35:299-301.
15. Valentini R.P., Imam A., Warrier I., et al. Sirolimus rescue for tacrolimus-associated post-transplant autoimmune hemolytic anemia. Pediatr Transplant 2006, 10:358-361.
16. Teachey D.T., Greiner R., Seif A., et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 2009, 145:101-106.
17. Trivedi H.L., Terasaki P.I., Feroz A., et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009, 87:1555-1561.
18. Lehrnbecher T., Foster C., Vázquez N., Mackall C., Chanock S. Therapy-induced alterations in host defense in children receiving therapy for cancer. J Pediatr Hematol Oncol 1997, 19:399-417.
19. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
20. Pasquini M, Wang Z. Current use and outcome of hematopoietic stem cell transplantation. CIBMTR Summary Slides. 2010. Available at: http://www.cibmtr.org.
21. Szabolcs P., Niedzwiecki D. Immune reconstitution after unrelated cord blood transplantation. Cytotherapy 2007, 9:111-122.
22. van Burik J., Carter S., Freifeld A., et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:1487-1498.
23. Gafter-Gvili A., Fraser A., Paul M., et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005, 142(12 Pt 1):979-995.
24. Massey E., Paulus U., Doree C., Stanworth S. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2009, 21:CD005341.
25. Goodman J., Winston D., Greenfield R., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326:845-851.
26. Slavin M., Osborne B., Adams R., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995, 171:1545-1552.
27. Perruccio K., Tosti A., Burchielli E., et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005, 106:4397-4406.
28. Lee S., Astigarraga C., Eapen M., et al. Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:1231-1238.
29. Leen A., Christin A., Myers G., et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009, 114:4283-4292.
30. Hanley P., Shaffer D., Cruz C., et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy 2011, [Epub ahead of print].
31. Amrolia P., Muccioli-Casadei G., Huls H., et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006, 108:1797-1808.
32. Castagnola E., Bagnasco F., Faraci M., et al. Incidence of bacteremias and invasive mycoses in children undergoing allogeneic hematopoietic stem cell transplantation: a single center experience. Bone Marrow Transplant 2008, 41:339-347.
33. Mullen C.A., Nair J., Sandesh S., Chan K.W. Fever and neutropenia in pediatric hematopoietic stem cell transplant patients. Bone Marrow Transplant 2000, 25:59-65.
34. Rocha V., Franco R., Porcher R., et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002, 100:3908-3918.
35. Azarian M., Busson M., Rocha V., et al. The PTPN22 R620W polymorphism is associated with severe bacterial infections after human leukocyte antigen geno-identical haematopoietic stem-cell transplantations. Transplantation 2008, 85:1859-1862.
36. Lee K., Park S., Kim I., et al. P2X7 receptor polymorphism and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Haematologica 2007, 92:651-657.
37. Chien J., Boeckh M., Hansen J., Clark J. Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. Blood 2008, 111:2462-2469.
38. Mensah N., Peterlongo P., Steinherz P., Pamer E., Satagopan J., Papanicolaou G. Toll-like receptor 4 polymorphisms and risk of Gram-negative bacteremia after allogeneic stem cell transplantation. A prospective pilot study. Biol Blood Marrow Transplant 2009, 15:1130-1133.
39. van der Velden W., Blijlevens N., Maas F., et al. NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation. Bone Marrow Transplant 2009, 44:243-248.
40. Hovi L., Saarinen-Pihkala U.M., Vettenranta K., Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant 2000, 26:999-1004.
41. Benjamin D.K., Miller W.C., Bayliff S., Martel L., Alexander K.A., Martin P.L. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J 2002, 21:227-234.
42. Safdar A., Rodriguez G., De Lima M., et al. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. Medicine (Baltimore) 2007, 86:324-333.
43. Dvorak C., Steinbach W., Brown J., Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005, 36:621-629.
44. Mikulska M., Raiola A., Bruno B., et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009, 44:361-370.
45. Marr K.A., Seidel K., Slavin M.A., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000, 96:2055-2061.
46. Kesh S., Mensah N., Peterlongo P., et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci 2005, 1062:95-103.
47. Seo K., Kim D., Sohn S., et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 2005, 36:1089-1095.
48. Zaas A., Liao G., Chien J., et al. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet 2008, 4:e1000101.
49. Bochud P.-Y., Chien J.W., Marr K.A., et al. Toll-like receptor 4 polymorphisms and Aspergillosis in stem-cell transplantation. N Engl J Med 2008, 359:1766-1777.
50. Mezger M., Steffens M., Beyer M., et al. Polymorphisms in the chemokine (C-X-C motif) ligand 10 are associated with invasive aspergillosis after allogeneic stem-cell transplantation and influence CXCL10 expression in monocyte-derived dendritic cells. Blood 2008, 111:534-536.
51. Cunha C., Di Ianni M., Bozza S., et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 2010, 116:5394-5402.
52. Granell M., Urbano-Ispizua A., Suarez B., et al. Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol 2006, 34:1435-1441.
53. Cohen J., Gandhi M., Naik P., et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005, 129:229-239.
54. Myers G., Krance R., Weiss H., et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005, 36:1001-1008.
55. Park S., Choi S., Lee D., et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis 2009, 11:413-423.
56. Jaskula E., Dlubek D., Duda D., Bogunia-Kubik K., Mlynarczewska A., Lange A. Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2009, 15:1296-1305.
57. Bogunia-Kubik K., Mlynarczewska A., Jaskula E., Lange A. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2006, 132:326-332.
58. Bogunia-Kubik K., Jaskula E., Lange A. The presence of functional CCR5 and EBV reactivation after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 40:145-150.
59. Cohen J. Clinical aspects of Epstein-Barr virus infection (chapter 5). Epstein-Barr Virus: Caister 2005, 35-55. Academic Press, New York. E. Robertson (Ed.).
60. Kieff E. Epstein-Barr virus and its replication. Fields Virology 2007, 2604-2654. Lipincott Williams & Wilkins, Philadelphia, PA. B. Fields, D. Knipe, P. Howley (Eds.).
61. Bollard C., Cooper L., HE H. Immunotherapy- targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol 2008, 21:405-420.
62. Rickinson A., Kieff E. Epstein-Barr virus. Fields Virology 2007, 2655-2700. Lipincott Williams & Wilkins, Philadelphia, PA. B. Fields, D. Knipe, P. Howley (Eds.).
63. Straus S. The chronic mononucleosis syndrome. J Infect Dis 1988, 157:405-412.
64. Kimura H., Hoshino Y., Kanegane H., et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001, 98:280-286.
65. Okano M., Kawa K., Kimura H., et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 2005, 80:64-69.
66. Suzuki K., Ohshima K., Karube K., et al. Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults. Int J Oncol 2004, 24:1165-1174.
67. Cohen J., Jaffe E., Dale J., et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood 2011, 117:5835-5849.
68. Swerdlow S., Webber S., Chadburn A., Ferry J. Post transplant lymphoproliferative disorder. Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 342-349. International Agency for Research on Cancer, Lyon, France. (4th ed). S. Swerdlow, E. Campo, N. Harris (Eds.).
69. Gottschalk S., Rooney C., Heslop H. Posttransplant lymphoproliferative disorders. Annu Rev Med 2005, 56:29-44.
70. Curtis R., Travis L., Rowlings P., et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999, 94:2208-2216.
71. Kennedy-Nasser A., Bollard C., Heslop H. Immunotherapy for epstein-barr virus-related lymphomas. Mediterr J Hematol Infect Dis 2009, 1:e2009010.
72. Shiramizu B, Wilkinson R, Hayashi R. Lymphoproliferative disorders and malignancies related to immunodeficiencies. In: Pizzo P, Poplack D, eds. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia, PA: Lipincott Williams & Wilkins, 683-702.
73. Heslop H. How I treat EBV lymphoproliferation. Blood 2010, 114:4002-4008.
74. Swinnen L. Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 2000, 11(suppl 1):45-48.
75. Faye A., Quartier P., Reguerre Y., et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001, 115:112-118.
76. Kuehnle I., Huls M., Liu Z., et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma afterhemopoietic stem-cell transplantation. Blood 2000, 95:1502-1505.
77. Skoda-Smith S., Douglas V., Mehta P., Graham-Pole J., Wingard J. Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant 2001, 27:329-332.
78. Comoli P., Basso S., Zecca M., et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007, 7:1648-1655.
79. Heslop H., Brenner M., Rooney C. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994, 331:679-680.
80. O'Reilly R., Small T., Papadopoulos E., Lucas K., Lacerda J., Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997, 157:195-216.
81. Bondanza A., Valtolina V., Magnani Z., et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 2006, 107:1828-1836.
82. Bonini C., Bondanza A., Perna S., et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 2007, 15:1248-1252.
83. Tey S., Dotti G., Rooney C., Heslop H., Brenner M. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:913-924.
84. Di Stasi A., Tey S., Dotti G. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011, In press.
85. Heslop H. Biology and treatment of Epstein-Barr virus assocated non-Hodgkin's lymphomas. Hematology Am Soc Hematol Educ Program 2005, 260-265.
86. Heslop H., Ng C., Li C., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996, 2:551-555.
87. Gustafsson A., Levitsky V., Zou J., et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000, 95:807-814.
88. Melenhorst J., Leen A., Bollard C., et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 2010, 116:4700-4702.
89. Heslop H., Slobod K., Pule M., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphproliferative diseases in transplant recipients. Blood 2010, 115:925-935.
90. Moosmann A., Bigalke I., Tischer J., et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010, 115:2960-2970.
91. Uhlin M., Okas M., Gertow J., Uzunel M., Brismar T., Mattsson J. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother 2010, 59:473-477.
92. Wilkie G., Taylor C., Jones M., et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases. J Immunother 2004, 27:309-316.
93. Haque T., Wilkie G., Taylor C., et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002, 360:436-442.
94. Haque T., Wilkie G., Jones M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110:1123-1131.
95. Gandhi M., Wilkie G., Dua U., et al. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 2007, 7:1293-1299.
96. Barker J., Doubrovina E., Sauter C., et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010, 116:5045-5049.
97. Leen A., Bollard C., Mendizabal A., et al. Most closely HLA-matched allogeneic virus specific cytotoxic T-lymphocytes (CTL) to treat persistent reactivation or infection with adenovirus, CMV and EBV after hemopoietic stem cell transplantation (HSCT). Blood (ASH Annu Meet Abstr) 2010, 116:829.